{Reference Type}: Journal Article
{Title}: Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study.
{Author}: Pozo-Rosich P;Ashina M;Tepper SJ;Jensen S;Boserup LP;Josiassen MK;Sperling B;
{Journal}: Neurol Ther
{Volume}: 13
{Issue}: 2
{Year}: 2024 Apr 18
{Factor}: 4.446
{DOI}: 10.1007/s40120-023-00575-5
{Abstract}: <B>BACKGROUND: </B>In the DELIVER study, eptinezumab reduced monthly migraine days (MMDs) more than placebo in patients with 2-4 prior preventive migraine treatment failures. This post hoc analysis evaluated the efficacy of eptinezumab across the 24-week placebo-controlled period of the DELIVER study in subgroups defined by prior treatment failure type.<BR><B>METHODS: </B>DELIVER (NCT04418765) randomized adults with migraine to eptinezumab 100 mg, 300 mg, or placebo, administered intravenously every 12 weeks. Changes from baseline in MMDs and percentages of patients with ≥ 50% reduction from baseline in MMDs (≥ 50% migraine responder rates [MRRs]) were summarized in subgroups of patients defined by prior treatment failure type. Subgroups were not mutually exclusive and included patients for whom topiramate, beta blockers (metoprolol, propranolol), amitriptyline, and/or flunarizine had failed.<BR><B>RESULTS: </B>Across Weeks 1-12 in all subgroups, patients treated with eptinezumab experienced greater reductions from baseline in MMDs than those receiving placebo (reductions ranged from 4.5-5.5 vs 1.6-2.4, respectively), with larger reductions over Weeks 13-24. Similarly, ≥ 50% MRRs were consistently higher with eptinezumab than placebo and increased following a second infusion.<BR><B>CONCLUSIONS: </B>In all subgroups, regardless of prior preventive treatment failure type, eptinezumab demonstrated greater reductions in MMDs and higher MRRs compared with placebo.<BR><B>BACKGROUND: </B>ClinicalTrials.gov (Identifier: NCT04418765).